Want to see OTLK full AI Analyst Report?
Top Page
Outlook Therapeutics
(NASDAQ:OTLK)
Select Model
Select Model
Rating:48Neutral
Price Target:
$0.49
▼(-23.75% Downside)
Action:Reiterated
Date:10/01/26
The score is held down primarily by very weak financial performance (persistent losses, heavy cash burn, and negative equity) and bearish technicals (below key moving averages with negative MACD). These are partially offset by a more constructive earnings-call outlook driven by FDA approval and detailed commercialization guidance, while valuation provides limited support due to negative earnings and no stated dividend.
Positive Factors
Regulatory Differentiation
FDA approval gives Outlook a differentiated, commercially viable product in a large retinal-care market. Being the only FDA-approved ophthalmic bevacizumab in U.S. wet AMD may support physician adoption, payer discussions, and a stronger position than repackaged alternatives.
Negative Factors
Persistent Unprofitability
Large recurring losses and limited revenue demonstrate that the business has not yet reached operating scale. Continued unprofitability can consume capital during commercialization, reduce flexibility to invest in growth, and make successful product adoption essential to improving earnings power.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Differentiation
FDA approval gives Outlook a differentiated, commercially viable product in a large retinal-care market. Being the only FDA-approved ophthalmic bevacizumab in U.S. wet AMD may support physician adoption, payer discussions, and a stronger position than repackaged alternatives.
Read all positive factors
Outlook Therapeutics (OTLK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$126.42M
Dividend YieldN/A
Average Volume (3M)4.32M
Price to Earnings (P/E)―
Beta (1Y)1.82
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.87
Shares Outstanding243,447,560
10 Day Avg. Volume3,999,399
30 Day Avg. Volume4,318,815
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.84
Price to Sales (P/S)19.10
P/FCF Ratio-0.52
Enterprise Value/Market Cap1.78
Enterprise Value/Revenue-193.10
Enterprise Value/Gross Profit-98.70
Enterprise Value/Ebitda-3.61
Forecast
1Y Price Target
$5.37Price Target Upside738.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$44.06M
Outlook Therapeutics Business Overview & Revenue Model
Company Description
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010,...
Outlook Therapeutics Earnings Call Summary
Earnings Call Date:Aug 14, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Dec 18, 2026
Earnings Call Sentiment Positive
The call conveyed a largely positive tone based on a transformational FDA approval, strong registrational efficacy data, clear commercial planning and recent financing to fund the U.S. launch. However, material risks remain: competitive pricing pressure from biosimilars, European commercialization challenges, reimbursement and patient affordability concerns, reliance on a J‑code and near‑term liquidity that required a public offering. Management positions the company to execute a measured launch with conservative forecasts and contingency upside if compounded bevacizumab availability changes.Positive Updates
FDA Approval of LYTENAVA
FDA approved LYTENAVA as the only FDA‑approved ophthalmic formulation of bevacizumab for wet AMD in the U.S.; management calls this transformational and a foundation for U.S. commercialization.
Negative Updates
Ongoing Competitive and Pricing Pressure
Market dynamics include multiple biosimilar entrants, downward pricing pressure, tenders and alternative therapies (TKIs, IL‑6s, gene therapy) assumed in the model; management explicitly modeled a competitive, price‑pressured environment.
Read all updates
Q3-2026 Updates
Positive
Negative
FDA Approval of LYTENAVA
FDA approved LYTENAVA as the only FDA‑approved ophthalmic formulation of bevacizumab for wet AMD in the U.S.; management calls this transformational and a foundation for U.S. commercialization.
Read all positive updates
Company Guidance
Management's financial and commercial guidance included first‑year U.S. launch net revenues of $50–75 million (with Europe ~10–15% of that), a front‑loaded ramp with ~10% of first‑year revenues in the first 3 months rising to ~50% in the fourth quarter after launch, and an anticipated permanent J‑code in April 2027 (HCPCS application targeted by end of Q3); pricing is planned with WAC below $500 per vial and R&D spend steady over the next 12 months while quarterly SG&A is expected to ~double by end‑2026 and then increase another ~10% during 2027. Operational and market metrics cited include hiring ~30 customer‑facing commercial and ~20 field reimbursement staff, sufficient supply for a late‑2026 launch, cash of $11.2M as of June 30 plus a $55M offering (≈$51.1M net), Q3 adjusted net loss of $10.9M ($0.09/share) versus $15.8M ($0.44), European unit sales +46% QoQ with Q4 units on track to match current, a $500M+ peak U.S. sales target by 2030 (base case) with ~+$300M upside if compounded bev is disrupted, and market context of an ~$8.5B U.S. anti‑VEGF market with ~3.6M repackaged bev injections in 2025 (≈2.2M for wet AMD); clinical data referenced NORSE TWO results (41.7% ≥15‑letter gains at month 11 vs 23.1% for ranibizumab).Outlook Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
5
Very Negative
Cash Flow
7
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -1.16M | 1.41M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.28M | 657.21K | 0.00 | 0.00 | -204.69K | 0.00 |
| EBITDA | -62.27M | -63.58M | -72.09M | -56.40M | -64.36M | -51.96M |
| Net Income | -61.12M | -62.42M | -75.37M | -58.98M | -66.05M | -53.16M |
Balance Sheet | ||||||
| Total Assets | 26.18M | 18.58M | 28.82M | 32.30M | 28.53M | 22.81M |
| Cash, Cash Equivalents and Short-Term Investments | 11.24M | 8.08M | 14.93M | 23.39M | 17.40M | 14.48M |
| Total Debt | 18.43M | 30.19M | 29.74M | 35.56M | 10.96M | 11.90M |
| Total Liabilities | 36.58M | 50.77M | 101.90M | 46.74M | 19.79M | 18.20M |
| Stockholders Equity | -10.39M | -32.19M | -73.08M | -14.44M | 8.74M | 4.61M |
Cash Flow | ||||||
| Free Cash Flow | -57.13M | -51.83M | -68.79M | -42.97M | -56.67M | -54.25M |
| Operating Cash Flow | -57.13M | -51.83M | -68.79M | -42.97M | -56.67M | -54.25M |
| Investing Cash Flow | -2.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 61.57M | 44.98M | 60.33M | 48.97M | 59.59M | 56.19M |
Outlook Therapeutics Technical Analysis
Negative
0.64
Price Trends
0.62
Negative
0.95
Negative
0.66
Negative
Market Momentum
-0.04
Negative
40.69
Neutral
66.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTLK, the sentiment is Negative. The current price of 0.64 is above the 20-day moving average (MA) of 0.56, above the 50-day MA of 0.62, and below the 200-day MA of 0.66, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 40.69 is Neutral, neither overbought nor oversold. The STOCH value of 66.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OTLK.
Outlook Therapeutics Risk Analysis
Outlook Therapeutics disclosed 75 risk factors in its most recent earnings report. Outlook Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Outlook Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
OTLK
Outlook Therapeutics
0.52
-0.82
-61.27%
ALDX
Aldeyra Therapeutics
0.65
-4.58
-87.59%
PRQR
ProQR
1.29
-1.57
-54.90%
Outlook Therapeutics Corporate Events
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Outlook Therapeutics Faces Nasdaq Minimum Bid Price Deficiency
Negative
Sep 30, 2026
On September 25, 2026, Outlook Therapeutics disclosed that it had received a notice from Nasdaq’s Listing Qualifications Staff stating that the company’s common stock had closed below $1.00 per share for 30 consecutive business days, b...
Business Operations and StrategyProduct-Related Announcements
Outlook Therapeutics Sets U.S. Price for LYTENAVA
Positive
Sep 18, 2026
On September 16, 2026, Outlook Therapeutics, Inc. set the U.S. wholesale acquisition cost for its ophthalmic therapy LYTENAVA™ at $485 per vial. The pricing decision defines an initial reference point for payers, providers, and patients, and...
Business Operations and StrategyExecutive/Board Changes
Outlook Therapeutics Announces CFO Transition and Board Change
Neutral
Aug 27, 2026
On August 23, 2026, Outlook Therapeutics and longtime finance chief and director Lawrence A. Kenyon agreed he would step down from his roles as chief financial officer, treasurer, corporate secretary, principal financial officer and principal acco...
Private Placements and FinancingRegulatory Filings and Compliance
Outlook Therapeutics Announces $55 Million Equity Offering
Positive
Aug 14, 2026
On August 12, 2026, Outlook Therapeutics entered into an underwriting agreement with Piper Sandler and BTIG for a public offering of 55,555,556 shares of common stock and accompanying warrants at a combined price of $0.99, with the deal expected t...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance
Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks
Negative
Aug 12, 2026
On July 24, 2026, Outlook Therapeutics announced U.S. FDA approval of LYTENAVA (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration, a milestone that makes its lead drug commercially viable but also heightens depend...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Outlook Therapeutics Gains FDA Approval for LYTENAVA Launch
Positive
Jul 24, 2026
On July 24, 2026, Outlook Therapeutics announced that the U.S. FDA approved its biologics license application for LYTENAVA, an ophthalmic formulation of bevacizumab for treating neovascular (wet) age-related macular degeneration. The drug becomes ...
Business Operations and StrategyExecutive/Board Changes
Outlook Therapeutics Grants Incentive Awards Tied to FDA Approval
Positive
Jul 24, 2026
On July 21, 2026, Outlook Therapeutics’ compensation committee granted stock options under its 2024 Equity Incentive Plan to Chief Executive Officer Robert C. Jahr and Chief Financial Officer Lawrence A. Kenyon, covering 100,000 and 210,078 ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.